Title

Physiological (TCR-like) regulated lentiviral vectors for the generation of improved CAR-T cells

María Tristán-Manzano¹*, Noelia Maldonado-Pérez¹*, Pedro Justicia-Lirio^{1,2}, Pilar Muñoz¹, Marina Cortijo-Gutiérrez¹, Kristina Pavlovic^{1,3}, Rosario Jiménez-Moreno³, Sonia Nogueras³, MDolores Carmona³, Sabina Sánchez-Hernández¹, Araceli Aguilar-González^{1,4}, María Castella⁵, Manel Juan⁵, Concepción Marañón¹, Karim Benabdellah¹, Concha Herrera³ and Francisco Martin^{1#}.

¹Department of Genomic Medicine, Pfizer-University of Granada-Andalusian Regional Government Centre for Genomics and Oncological Research (GENYO), PTS, Avda. de la Ilustración 114, 18016 Granada, Spain.

²LentiStem Biotech, Pfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research (GENYO), PTS, Avda. de la Ilustración 114, 18016 Granada, Spain.

³Maimonides Institute of Biomedical Research in Córdoba (IMIBIC), Cellular Therapy Unit, Reina Sofia University Hospital, University of Córdoba, Córdoba, Spain.

⁴Department of Medicinal and Organic Chemistry, Faculty of Pharmacy, University of Granada, Campus Cartuja, 18071 Granada, Spain.

⁵Department of Hematology, ICMHO, Hospital Clínic de Barcelona, Villarroel 170, 08036 Barcelona, Spain.

*Share authorship

Corresponding author: Francisco Martin.

Gene and Cell therapy Unit, Department of Genomic Medicine, Pfizer-University of Granada-Andalusian Regional Government Centre for Genomics and Oncological Research (GENYO), PTS, Avda. de la Ilustración 114, 18016 Granada, Spain.

francisco.martin@genyo.es

Running title: TCR-like LVs for improved CAR-T

List of abbreviations

1

- 2 ATMP: advanced therapy medical product.
- 3 B-ALL: B-acute lymphoblastic leukaemia.
- 4 CAR: Chimeric Antigen Receptor.
- 5 CMV: Cytomegalovirus.
- 6 eGFP: enhanced green fluorescent protein.
- 7 EF1α: Elongation Factor 1- α
- 8 EMA: European Medicine Agency.
- 9 FDA: Food and Drug administration.
- 10 LVs: Lentiviral vectors.
- 11 LTR: long-terminal repeats
- 12 MSCV: murine stem cells virus
- 13 NTD: non-transduced cells.
- 14 R/R: relapsed/ refractory.
- 15 ScFv: Single chain variable fragment.
- 16 SFFV: Spleen focus forming virus.
- 17 TCR: T cell receptor.
- 18 TCM: T central memory.
- TEF: T effectors.
- 20 TEM: T effectors memory.
- 21 TN/SCM: T naïve/stem cell memory.
- 22 TRAC: T cell receptor (TCR) constant alpha locus
- 23 WAS: Wiskott-Aldrich syndrome.

ABSTRACT

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

Background. Chimeric antigen receptor (CAR) T cells directed against CD19 have achieved impressive outcomes for the treatment of relapsed/refractory B lineage lymphoid neoplasms. However, CAR-T therapy still has important limitations due to severe side effects and the lack of efficiency in 40-50% of the patients. Most CARs-T products are generated using retroviral vectors with strong promoters. However, high CAR expression levels can lead to tonic signalling, premature exhaustion and over-stimulation of CAR-T cells, reducing efficacy and increasing side effects. TCR-like expression of the CAR through genome editing resulted in enhanced anti-tumour potency, reducing tonic signalling and improving CAR-T phenotype. In this manuscript, we searched for LVs that mimic the TCR expression pattern as a closer-toclinic alternative for the generation of improved CAR-T cells. **Methods.** Different LVs containing viral and human promoters were analysed to select those that closely mimic a TCR-like kinetic profile upon T-cell activation. WAS gene proximal promoter-driven LVs (AW-LVs) were selected to express a second generation 4-1BB αCD19 CAR (ARI-0001) into T cells to generate AWARI CAR-T cells. TCR-like AWARI and EF1αdriven ARI CAR T cells were analysed for in vitro and in vivo killing efficiency using leukaemia and lymphoma cellular models. Tonic signalling, exhaustion markers and phenotype were determined by flow cytometry. Large-scale automated manufacturing of AWARI CAR-T cells was performed in a CliniMACs Prodigy bioreactor. Results. Our data showed that LVs expressing the transgene through the WAS gene proximal promoter mimic very closely the TCR (CD3) expression pattern kinetic upon TCR stimulation or antigen encounter. Compared to EF1α-driven ARI CAR-T cells, AWARI CAR-T cells exhibited a higher proportion of naïve/stem cell memory T cells with less exhausted phenotype after efficient killing of CD19+ cells both in vitro and in vivo. AWARI CAR-T cells also showed lower tonic signalling and reduced secretion of pro-inflammatory cytokines and were efficiently manufactured in large-scale GMP-like conditions.

1 Conclusions. WAS-gene-promoter driven LVs can be used to generate physiological 4-1BB-

CAR-T cell products with lower tonic signalling, improved phenotype and a safer profile. We

propose the use of TCR-like LVs as an alternative to strong-promoter driven LVs for the

generation of CAR-T products.

5 Keywords

2

3

4

9

10

6 CAR-T; Physiological expression; TCR-like expression; Lentiviral vectors; tonic signalling;

7 Pro-inflammatory cytokines, Exhaustion; CAR silencing; WAS gene promoter; Stem Cell

8 Memory T cells.

BACKGROUND

11 Chimeric antigen receptor (CAR) T cells have become one of the most promising approaches 12 for the treatment of cancer in particular for B lineage lymphoid neoplasms using αCD19-CAR-T 13 cells, as emphasized with four FDA/EMA-approved Advance Therapy Medicinal Products 14 (ATMPs): tisagenlecleucel (Kymriah, Novartis), axicabtageneciloleucel (Yescarta, Kite-Gilead), 15 brexucabtagene autoleucel (Tecartus, Kite-Gilead) and lisocabtagenemaraleucel (Breyanzi, 16 Bristol Myers Squibb). However, in spite of the impressive results of αCD19-CAR-T cells, 17 there are still several aspects that must be improved. Aggressive severe side effects due to CAR-18 T overstimulation, such as cytokine release syndrome (CRS) and neuroinflammation are 19 common among treated patients and can lead to fatal outcomes. Furthermore, sustained 20 complete remissions range from 62% to 42% for patients treated with commercial ATMPs, 21 evidencing much room for improvement¹. 22 Different works have uncovered the importance of controlling CAR expression levels at the surface of the CAR-T cells in order to optimize its therapeutic activity ²⁻⁴. In spite of this, all 23 24 four approved ATMPs approved and most of those that are been tested in ongoing clinical trials 25 use autologous T cells transduced with retroviral vectors expressing a αCD19-CAR through 26 constitutive, strong promoters such as the human EF1α and the murine stem cell virus LTR

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

23

24

25

26

27

(MSCV). High CARs concentrations on the T cell surface can result in spontaneous clustering of the CARs (independent of the ligand) leading to tonic-signalling ⁴⁵. This tonic signalling can affect safety (pro-inflammatory cytokines secretion in non-target tissues) and efficacy (premature exhaustion due to continuous proliferation) of CAR-T cells³⁻⁵. Furthermore, highdensity and constitutive CAR presence on the T cell surface can also lead to overstimulation upon antigen recognition that also affect safety (excess of pro-inflammatory cytokine secretion) and efficacy (early exhaustion, apoptosis and loss of $T_{N/SCM}$ phenotype) of the CAR-T cells^{2, 3}. In this direction, Eyquem et al. generated CAR-T cells expressing the αCD19-28ζ CAR through the endogenous T cell receptor constant alpha chain (TRAC) locus using CRISPR/Cas9². In this manuscript, the authors concluded that tight transcriptional regulation of CAR expression, lowering CAR levels upon target binding and recovering 1-3 days later, was critical for optimal CAR-T performance. However, despite the great potential of genome editing tools for therapeutic applications, there are still several technological and safety issues that need to be solved before the approval of genome edited cells as ATMPs. Contrary to genome editing tools, lentiviral vectors (LVs) derived from HIV-1 have already been approved by the FDA and EMA (Kymriah, Breyanzi and Zynteglo). Latest generation LVs are very resistant to transgene silencing^{6,7}, and allow the control of the transgene through physiological or drug inducible promoters⁸⁻¹³. We therefore searched for LVs that express transgenes on T cells following a TCR expression kinetic. Since the TRAC promoter in human mature T cells is not well defined, we focus in a well-defined promoter that controls the 21 expression of the WASP protein, which is involved in the formation of the immunological synapse and in translating TCR signals to several T cells functions^{14,15}. We reason that WAS-22 promoter driven LVs 8 11 16 could be an interesting option to express CARs due to their moderate expression levels and the functional relationship with the TCR. Here we showed that, indeed, WAS-promoter driven LVs partially mimicked the TCR expression kinetic both in eGFP- and CAR-expressing LVs, with a small down-regulation upon stimulation and recovering basal levels in 5-7 days. Based on these data, we generated TCR-like CAR-T cells using LVs and

1 analysed potential improvements compared to standard CAR-T cells expressing the CAR

through strong promoters. TCR-like expression of a α CD19-CAR lead to lower tonic signalling

in the absence of antigen as well as a better response in its presence, with lower exhaustion

markers, lower proinflammatory cytokine secretion and improved phenotype both in vitro and

in vivo.

2

3

4

5

6

7

12

13

24

MATERIALS and METHODS

Cell culture

- 8 Nalm6 (ATCC® CRL-3273), Namalwa (ATCC® CRL-1432), Jurkat (ATCC® TIB-152), HL-
- 9 60 (ATCC® CCL-240) and HEK-293T (ATCC® CRL-11268) cells were cultured as described
- 10 elsewhere. Namalwa and Nalm6 were modified to express enhanced GFP (eGFP) and
- Nanoluciferase (NanoLuc) using the SELWP, as described previously¹⁷.

Human samples

- 14 Primary T cells were isolated from fresh or frozen apheresis products obtained from healthy
- donors at the Hematology Department of the Hospital Universitario Reina Sofía (Córdoba,
- Spain). All donors gave their written informed consent and the study was performed according
- 17 to the guidelines of the local ethics committee and complies with the requirements regarding
- 18 quality and safety for donation, obtaining, storage, distribution, and preservation of human cells
- and tissues under the Spanish specific regulation (RD-L 9/2014). Pan-T cells were isolated by
- 20 negative selection using immunomagnetic beads (Pan T cell Isolation Kit, Miltenyi Biotec) and
- 21 following MACSExpress Separator (Miltenyi Biotec) or AutoMACs Pro Separator's (Miltenyi
- 22 Biotec) protocol and cultured in TexMACS (Miltenyi Biotec) supplemented with 20 UI/ml of
- 23 IL-2 (Miltenyi Biotec). T cells were activated with T Cell TransAct (Miltenyi Biotec).

Plasmid constructs

- 25 To construct the SELWP vector, a self-inactivated (SIN) LV expressing eGFP and NanoLuc
- under the spleen focus-forming virus (SFFV) promoter, an eGFP-P2A-NanoLuc (NanoLuc

1 sequence obtained from GeneBank accession: JQ437370. Nucleotides 100-616) flanked by

AscI/SbfI restriction sites was designed and synthesized by Genscript (Genscript USA Inc. NY,

3 U.S.A). The eGFP-P2A-NLuc was cloned into the SEWP LV ¹⁸ by standard molecular biology

4 techniques to obtain the SELWP.

2

12

14

15

16

17

18

19

20

21

24

25

5 We used self-inactivated LVs-driven eGFP already available in our laboratory. SE¹⁶, CEWP¹⁰

6 and EFEWP (our laboratory) driving eGFP under the control of SFFV, cytomegalovirus, and

7 EF1a promoters, respectively. WAS-promoter based LVs: WE-LVs harbours 0.5kb of the WAS

8 proximal promoter¹⁶, and the AWE-LVs include 0.5kb of the WAS proximal promoter and 0.38

9 kb of the alternative promoter⁸.

10 For AWARI LVs generation, the AW promoter were obtained from the AWE 8 by ClaI / BamHI

and inserted into the ARI-0001 plasmid¹⁹, replacing the EF1 α promoter.

Lentiviral vector production and titration

13 Lentiviral vectors were generated by co-transfection of HEK-293T cells with the plasmid of

interest, the plasmid pCMVDR8.91 and the p-MD-G plasmid as previously described 12. LVs

were concentrated by ultracentrifugation at 90.000g for 2h at 4°C, resuspended in TexMACs

and storaged at -80°C. LVs titters were determined by transducing Jurkat cells with different

dilutions of viral supernatant. Percentage of positive cells was determined by flow cytometry

and transducing units per ml (TU/ml) were estimated according to the formula: (10⁵ plated cells

 \times % of positive cells)]/ml of LV.

T cell transduction

22 Activated primary T cells were transduced with the different LVs at a multiplicity of infection

23 (MOI) of 10 through spinoculation (800 x g for 60 min at 32°C). Media was exchanged after 5

hours of incubation. At 4-6 days after transduction, the percentage of transduced cells was

determined by flow cytometry.

Expression pattern analysis of LVs on T cells

2 For T cells transduced with eGFP-LVs, 10⁵ T cells were stimulated with TransAct (Miltenyi

3 Biotec) after 10 days of the initial activation for transduction. Similarly, 10⁴ transduced CAR-T

cells were stimulated with 10⁴ CD19+ Namalwa-GFP-NLuc cells in order to simulate the

5 CAR/TCR signalling axis in U-bottom 96-wells plates. eGFP or CAR expression was

determined at different time-points after stimulation. Cells were stained and fixed with 2% PFA

prior FACS acquisition. Expression was indicated as the ratio of MeFI of positive population

against the MeFI of non-transduced total population. Fold change indicates the ratio of

expression or percentage related to those values at 0h.

Flow cytometry

1

4

6

7

8

9

10

16

21

22

23

25

11 CAR expression was determined with a biotin-conjugated goat anti-murine Fab SP-longer

12 Spacer IgG (Jackson Immunoresearch) and APC-conjugated streptavidin (ThermoFisher). For

13 human T cell phenotyping the following mAbs were used: CD45RA-PE/FITC (HI-100),

14 CD62L-PE-Cy7 (DREG56), CD3-PerCP-Cy5/APC-780 (OKT3), PD1-APC (MIH4), LAG-3-

15 PE (3DS223H), TIM-3-APC-Cy7 (F38-2E2) all from eBioscience (ThermoFisher). Tonic

signalling was determined by intracellular staining with pCD3z-PE (Tyr142, 3ZBR4S) and Fix

17 & Perm Kit (Nordic Bio). Samples were acquired on a FACSCantoII cytometer. FlowJo

software (TreeStar) was used for data analysis.

19 Cytokine secretion of CAR-T cells

To analyse cytokine production after T cells stimulation, $5x10^4$ CAR-T cells were co-cultured

with Namalwa-GFP target cells at ratio 1:1 in TexMACs without any supplement. Supernatants

were collected after 24h and frozen at -80°C. TNFα and IFN□ were measured with anti-human

TFN-α Ready-SET-Go! Kit of Affymetrix (eBioscience) and ELISA MAX Deluxe Set

24 (Biolegend) respectively following manufacturer's instructions.

Cytotoxicity assay

1

9

- 2 Target cells (CD19+), such as Namalwa and Nalm-6 cells expressing GFP-Nluc, and non-target
- 3 cells (CD19-) HL60 cells (unlabelled), were co-cultured at a concentration of $5x10^3$ cells per
- 4 well in duplicate in 96-well U-bottom plates, and incubated with T cells at various effector-
- 5 target (E:T) ratios (0.5:1, 1:1, 2:1) in non-supplemented TexMACs during 16h or 48h as
- 6 indicated. Percentage of lysis was determined by flow cytometry related to basal lysis produced
- by non-transduced T cells. Specific lysis was determined as follows: 1-(%CD19+ /% HL-60 in
- 8 CAR-T cells condition/ %CD19+/%HL-60 in NTD condition) x100.

In vivo xenograft animal model and bioluminescence analysis

10 10 to 12-weeks-old NOD/scid-IL-2Rnull (NSG) mice were inoculated intravenously with 3x10⁵ 11 Namalwa-GFP-NLuc cells per mice, and three days later, mice were randomly infused with CAR-T cells (5x10⁶ or 10x10⁶), non-transduced T cells (5x10⁶ or 10x10⁶) or PBS in the tail's 12 13 vein. Re-challenge was assessed by re-inoculating intravenously a new dose of Namalwa-GFP-Nluc cells. Our experiments are based on a modified randomized block design in which each 14 15 block receives more than one treatment at different periods. Subjects were randomly assigned to 16 receive the different treatments (PBS, T cells or CAR-T cells). This will allow a comparison 17 between the different treatment groups in pairs (each one compared to the control and each one 18 compared to each other). For the estimation of the sample size in each experiment, we 19 calculated the sample size necessary to obtain a p≥0.05 to be of n≥5 for controls/CAR-T 20 comparison and an n>8 for AWARI/ARI comparisons based on Mayer et al²⁰. For 21 bioluminescence analysis, furimazine (Nano-Glo, Promega) was diluted at 1/60 in PBS and 22 injected intraperitoneally immediately prior to acquisition on an IVIS Spectrum analyzer 23 (Caliper, Perkin Elmer). Images were acquired during 180s, open field, and analysed using the 24 Living Image 3.2 (Perkin Elmer) or AURA Imaging Software 3.2 (Spectral Instruments 25 Imaging). Mice were sacrificed if experiencing a weight loss greater than 20% or at the 26 indicated days. Samples of blood, bone marrow, liver, spleen and brain were collected. Blood 27 was extracted and diluted 1/5 in EDTA. Cells were obtained from liver and spleen by 1 mechanical disruption and from bone marrow by the perfusion of both femurs and tibias.

Brain's cells were obtained after Percoll-gradient separation. Percentage of surviving Namalwa-

3 GFP-Nluc and T cells (hCD3+) were determined by FACS in the singlet's gate and then in

"human cells" gate, which was previously established after acquiring an artificial mixture of

5 Namalwa cells and human T cells used as control.

2

4

6

8

9

10

11

GMP-like manufacturing of CAR-T cells on CliniMACs Prodigy

7 Large scale manufacturing of CAR-T cells on CliniMACs Prodigy was carried out under GMP-

like conditions into Gene-Cell Therapy cleanrooms of Cell Therapy Unit of Hospital

Universitario Reina Sofía (Córdoba, Spain). Two different apheresis from a healthy donor was

thawed and around 100x10⁶ T cells were inoculated into the CliniMACs prodigy bioreactor

(Miltenyi Biotec). CD4 and CD8 cells were selected with CD8 and CD4 Reagent (Miltenyi

12 Biotec), cultured with IL-7/IL-15 (Miltenyi Biotec) and activated with αCD3/αCD28 GMP T

13 cell TransAct (Miltenyi Biotec). At day 2 of the process, these cells were transduced with

14 AWARI-LVs (MOI=5). Cells were cultured in TexMACs GMP medium containing GMP-grade

15 IL-15 and IL-7 (Miltenyi Biotec) for 9 or 10 days. Final product was collected with 100ml of

NaCl 0.9% + 0.5% human serum albumin (HSA).

17 Cells were stained with CD3-APC, CD4-FITC, CD8-APC Vio770, CD14-PE Vio770, CD45-

18 Vioblue (Miltenyi Biotec). To assess the efficiency of transduction CAR-T cells were stained

19 with CD-19 Biotin and Anti-biotin PE (Miltenyi Biotec). Viability was tested by using 7AAD

20 (Miltenyi Biotec). Phenotype was determined with CD45RA-APC (HI100) and CCR7-BV421

21 (2-L1-A RUO) from BD Pharmingen. Cells were acquired on a MACsQuant cytometer

(Miltenyi Biotec) and analyzed with MACsQuantify Analysis Software (Miltenyi Biotec).

Data analysis

22

23

24 Statistical analyses were performed using GraphPad 1.6 software (GraphPad Software Inc., La

25 Jolla, CA). Data were expressed as the mean ± SEM. Each performed statistical test was

1 indicated in every figure caption. Survival curves were constructed using the Kaplan-Meier

2 method.

3

25

RESULTS

4 5 WAS promoter-driven LVs mimic the TCR expression pattern upon T-cell activation 6 As LVs have already been approved by EMA and the FDA, LVs expressing the CARs with a 7 similar kinetic than the TCR (TCR-like LVs) could be a real alternative to existing LVs to 8 generate more potent and safer CAR-T cells. We first investigated whether WAS-promoterdriven LVs could have a more physiological expression pattern compared to current LVs used 9 for CAR-T cells generation. We generated eGFP-expressing LVs particles from two different 10 WAS-promoter-driven LVs (Fig. 1A, WE and AWE)^{8, 16} and three LVs driven by strong 11 12 promoters (Fig. 1A, CEWP, SE and EFEWP). 13 In order to analyse if the WAS-promoter-driven LVs mimic the TCR expression pattern, we first 14 studied the CD3 expression levels (Fig. 1B and Fig. S1a) of primary human T cells after 15 stimulation with αCD3/αCD28 nanomatrix and CD19+ cells (in CAR+ cells, Fig 1B and Fig 16 S1b) at different time-points. In parallel, T cells transduced with the different eGFP-expressing 17 LVs were stimulated and analysed by flow cytometry as described in Fig. 1A. As it has been reported previously², CD3 expression in T cells decreased soon after stimulation reaching 18 19 minimal expression at 24h/48h at both protein and mRNA levels and recover basal levels after 20 5-7 days (Fig 1B, S1a). Contrary to the CD3 expression pattern, all LVs harbouring 21 constitutive-strong promoters (EF1\(\alpha\) (EFEWP), SFFV (SE) and CMV (CEWP)), behaved in an 22 opposite manner, increasing eGFP expression soon after T cell stimulation (Fig. 1C-top panels, 23 **1D** and **1E**-orange line). Interestingly, WAS-promoter driven LVs partially mimicked the TCR 24 expression kinetic, down-regulating eGFP expression upon stimulation that peak at 48h and

recover basal levels after 7 days (**Fig. 1C**-bottom panels, **1E**-blue and green lines).

1 We next investigated whether CARs expressed by WAS-promoter driven LVs also followed a 2 TCR-like kinetic. We constructed the AWARI LV (see M&M for details) based on the ARI-0001 LV backbone²¹, a CAR19-BBzz recently approved as ATMP in Spain, which uses the 3 4 A1B6 clone as scFv (Fig. 1F). We then generated ARI and AWARI CAR-T cells using the ARI 5 and AWARI LVs and analysed their CAR expression kinetic upon activation with CD19+ cells 6 (Fig 1G-left,1H and S1B-left) or αCD3/αCD28 (Fig 1G-right, 1I and S1B-right). Interestingly, 7 AWARI CAR-T cells showed a down-regulation of CAR levels after antigenic stimulation and 8 a recovery after 48h (Fig. 1H, 1I, blue line; Fig. 1G, bottom panel), while ARI CAR-T cells 9 showed a clear increment on CAR levels after T cell activation (Fig. 1H, 1I, green lines, Fig. 10 **1G**, top panel). A similar behaviour was also observed when using a third generation αCD19-11 CAR-28BBzz (Fig S1C, S1D). Altogether, our results showed that the AW-LVs can be used to 12 generate CAR-T cells expressing the CAR in a TCR-like manner. 13 14 TCR-like expression of CAR prevents exhaustion and control proinflammatory cytokines 15 secretion upon antigen exposure in vitro We next compared the behaviour of 2nd generation ARI versus AWARI CAR-T cells. First, we 16 17 measured basal levels of exhaustion markers (LAG-3, PD1, Tim3) (Fig. 2A) and tonic 18 signalling (phospho-CD3z) (Fig. 2B) in a CD19-independent context. AWARI CAR-T cells 19 expressed significant lower levels of LAG-3 and Tim3 (and also a trend for PD1) (Fig. 2A) and 20 less phosphorylation of CD3z (Figure 2B). Both CAR-T cells efficiently killed CD19+ Nalm6 21 (B-ALL derived) and Namalwa (Hodgkin's lymphoma derived), without significant differences 22 (Fig. 2C). Interestingly, LAG-3 expression levels were significantly lower in AWARI 23 compared to ARI CAR-T cells after killing Namalwa cells (Fig. 2D, right). In addition, AWARI 24 CAR-T cells secreted lower levels of TNF α and IFN γ compared to ARI cells (Fig. 2E), 25 indicating a more controlled proinflammatory activity. We also observed a tendency of 26 increased stem memory T cells (CD45RA+CD62L+) population in AWARI versus ARI CAR-T 27 cell (but not statically significant, Figs. S2D, S2E). Finally, similar observations were found when 3rd generation CARs (CAR19-28BBzz) were expressed with the AW-LVs in terms of

2 lower tonic signalling (**Fig S2A**) and milder IFNy secretion (**Fig. S2B**).

AWARI CAR-T cells are as efficient as ARI CAR-T cells eradicating CD19+ tumour cells

in vivo and maintain a more stem-like phenotype.

3

4

5

25

26

6 In vitro cytotoxicity experiments only represent a direct-short term activity of CAR-T cells. We 7 therefore performed a direct comparison of the anti-tumour activity of ARI versus AWARI 8 CAR-T cells in a xenograft mice model of human lymphoma using two different CAR-T doses 9 and a re-challenge after first lymphoma cells clearance (Fig. 3A, See M&M for details). Both 10 CAR-T cells efficiently eliminated Namalwa tumour cells in treated mice with both doses (Figs. 11 **3B, 3C** and **Fig. S3A**). However, a small amount of Namalwa cells (less than <5%) were 12 detected in liver of some ARI-mice and in brain of some AWARI-mice treated with the low 13 dose (Fig. 3C, left panels). Importantly, CAR expression driven by the two vectors was 14 maintained in all the organs after sacrifice (Fig. 3D), even with a second-challenge, when 15 compared to those ex-vivo levels prior to infusion (Fig. S3B), indicating no promoter silencing. 16 After showing the same therapeutic efficacy, we investigated potential differences in CAR-T 17 cell phenotype after tumour clearance. Interestingly, AWARI-CAR-T cells showed a higher 18 proportion of memory (T_{CM}: CD45RA-CD62L+) and stem memory (T_{SCM}: CD45RA+CD62L+) 19 (Fig. 3D) cells in spleen, bone marrow (BM), blood and liver when compared to ARI-treated 20 mice (Fig.3E, 3F). Specially after re-challenge (inner circle, Fig. 3E), T_{SCM} population of 21 AWARI-CAR-T cells was increased in spleen and liver and T_{CM} subset in BM and brain. In 22 order to further characterize the potential differences, we cultured the cells from processed 23 spleens during 48h in vitro with 200 UI/ml of IL-2 in TexMACs medium (Fig. 3G), and we 24 confirmed an increment in T cell memory populations in AWARI-derived spleens (Fig. 3H, 3I)

and a tendency to have lower expression of exhaustion markers (PD1+LAG3+) (Fig. 3H, 3J).

Large-scale semi-automated manufacturing of AWARI CAR-T cells

1

2 Before translation of AW-LV to ATMP production for clinical applications, it is important to 3 demonstrate their performance for large-scale automated manufacturing. We therefore used 4 laboratory grade AWARI LVs to generate two batches of CAR-T cells (#01 and #02) in the 5 CliniMACs Prodigy Bioreactor (Miltenyi Biotec) under GMP conditions (see M&M). Samples 6 at days 7 and 10 for batch #01, and 6 and 9 days for batch #02 (Fig. 4A) were collected to study 7 CAR expression (Fig. 4B), viability, expansion (Fig 4C), CD4/CD8 ratio (Fig. 4D), phenotype 8 (Fig. 4E), and in vitro lytic activity (Fig. 4F). In both productions processes, cells were 9 efficiently expanded, with more CD4+ than CD8+ CAR+ cells and prominent T_{N/SCM} (CCR7+ 10 CD62L+) subset $(44.85 \pm 0.07\%)$ at day 7 or day 6, that were drastically reduced at final day of 11 the production (16,55 \pm 13.93%), turning into T_{CM} cells but with minimal effector and effector 12 memory populations (Fig. 4E). As described for other CAR-T cell products, lower expansion 13 times rendered more potent AWARI CAR-T cells (Fig. 4F). All these results point out to the 14 AWARI LVs as a valuable tool for a future clinical trial, although improvements in its lentiviral 15 backbone could further increase transduction efficacy in order to lower costs and time of 16 production. 17 18 Large-scaled manufactured AWARI CAR-T cells products are highly efficient for tumour 19 clearance and maintain good levels of T_{N/SCM} cells in vivo. 20 Finally, we performed a detailed analysis of large-scale manufactured AWARI CAR-T cells in 21 terms of their in vivo anti-tumour efficacy and their phenotype after isolation from treated mice 22 (Fig. 5) for both #01 (blue dots) and #02 (green dots) CliniMACS batches. Anti-tumour activity 23 of both AWARI CAR-T cells products were analysed in the Namalwa xenograft mice model as 24 depicted in Fig 5A. Survival (Fig. 5B) and tumour progression (Figs. 5C and 5D) were 25 monitored up to 28-30 days post-treatment showing a strong anti-tumour activity of the AWARI 26 CAR-T cells with 100% survival and undetectable tumour cells in treated mice (Figs. 5C, 5D 27 and Fig, S4A). Control PBS and NTD- inoculated mice developed the disease at similar rates

and the majority required to be sacrificed for compassionate reasons at days 13-16. At this time point, the stemness of human CAR-T cells of two AWARI-treated mice (**Fig. 5F** top panel, **S4C**) in #01 experiment was clearly maintained. New Namalwa cells were inoculated in AWARI-T cells-treated mice and also in new mice ("New PBS"). Re-challenged AWARI-mice remained tumour-free through the duration of the experiment as did the follow-up group. Similar results were observed in both productions (**Fig. 5C, 5D, S4A**). The percentage of CAR+cells (**Fig 5E**) was maintained before (*ex-vivo*) and after *in vivo* elimination of Namalwa cells in the xenograf model with a slight increase in some of the organs (**Fig. S4b**). Importantly, the phenotypic analysis confirmed the presence of a high proportion of T_{SCM}/T_{CM} populations (**Fig. 5E, 5F, S4D**) at the end point of rechallenged and non-rechallenged mice. However, a significant reduction of these populations was observed from day 13 to day 30 (**Fig. 5F top panel, S4C**). This data confirmed the *in vitro* (**Fig. S2**) and *in vivo* (**Fig. 3**) results showing that the expression of the ARI-CAR19-BBzz through a TCR-like promoter (AWARI-CAR-T cells) maintains the proportion of T_{SCM}/T_{CM} CAR-T cells upon antigen encounter.

DISCUSSION

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

αCD19 CAR-T cells have achieved impressive therapeutic benefits in R/R B lineage lymphoid neoplasms, leading to the approval of Kymriah, Yescarta, Tecartus and Breyanzi and over 800 clinical trials around the globe. Most of these studies have used autologous T cells that are gene modified by retrovirus-based vectors to express the CAR through a strong promoter (often the EF1α or MSCV promoters). However, CAR-T therapy still has important limitations due to severe side effects and the lack of complete cures in 40-62% of the CD19+ lymphomas ¹ and most solid tumours^{22,23}. Improvements in CAR structure (scFV, hinge/spacer, costimulatory domains, bi-especific or multispecific CARs, etc) T cell composition or combinational therapies have already shown improved results²⁴. New approaches to improve CAR-T efficacy and/or safety include the control of CAR activity and or other molecules¹³ and mechanism to avoid immune-reactions against the CAR-T cells²⁵. There are several evidences indicating that high levels and continuous expression of the CAR can be deleterious for the efficacy and safety of the CAR-T products²⁻⁴. The loss of efficacy comes in part from the early exhaustion and/or apoptosis of the CAR-T cells due to an excess of CAR signalling after antigen encounter²⁶. Strong and unregulated CAR expression also increase tonic signalling in the absence of target antigen⁴ promoting exhaustion^{3, 5}. On the other side, safety issues due to CAR overexpression relates to the increased antigen-independent tonic signalling and to over-stimulation of CAR-T cells that generate CRS. Using genome editing technologies, Eyquem et al. demonstrated that TCR-like expression of CARs resulted in lower tonic signalling, reduced CAR-T exhaustion and increased proportion of TSM/TN CAR-T cells, resulting in improved anti-tumour activity². These authors also showed that low expression was not enough to achieve optimal CAR-T products, concluding that a down-regulation of the CAR upon antigen encounter was required for optimal CAR-T performance. In this manuscript we investigated whether LVs can be used to obtain a TCR-like expression kinetics that could also result in an improved CAR-T cell product. Our search for human

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

promoters that could mimic the TCR expression pattern pointed to the TRAC locus, however, the TRAC promoter in mature human T cells is not well defined. We therefore focus on the WAS gene promoter because WASP protein is only expressed in hematopoietic cells, is involved in the formation of the immunological synapse and acts as an adaptor of TCR signals^{14,15}. We have previously developed different WAS-gene based promoters and identified the AW promoter, harbouring fragments from the alternative and proximal promoter, as the best option to express transgenes in hematopoietic cells^{8, 11, 16}. Here we showed that, indeed, WAS-promoter driven LVs (AW-LVs) partially mimicked the TCR expression kinetic, with a small downregulation upon stimulation and recovering basal levels in 5-7 days. Based on the ability of AW-LVs to mimic TCR expression pattern on T cells, we investigated whether 4-1BB-CAR-T cells generated with this "physiological" LVs have a better behaviour compared to that generated with LVs harbouring strong or viral promoters. Although in terms of in vitro or in vivo anti-tumour activity we could not detect significant differences with EF1αdriven CAR-T cells, AW-CAR-T cells exhibited lower tonic signalling and a better phenotype after efficient killing of CD19+ cells, with reduced secretion of pro-inflammatory cytokines. These data is largely in agreement with the observations of Eyquem et al. using genome editing technologies to express the CAR through the TRAC locus². However, these authors also showed improved in vivo anti-tumour activity². The differences in the tumour model (Nalm6 versus Namalwa) as well as in the CAR signalling domain (CD28 versus 4-1BB) and scFv (FMC63 versus A3B1) could explain the observed differences. Indeed, the potential deleterious effects of CAR over-expression and tonic signalling are highly influenced by the CAR configuration^{2, 4}. For instance, replacing CD28 with the 4-1BB costimulatory domain reversed exhaustion in CAR T cells and improved its persistence and therapeutic efficacy²⁷. The good behaviour of EF1α-driven 4-1BB-CARs T cells and the experimental limitations derived by the graft versus host disease (GVHD) caused by the administration of the CAR-T cells can explain the absence of increased therapeutic efficacy in our animal models.

3

4

5

6

7

8

9

10

11

12

13

14

15

17

18

19

26

27

In spite of the good behaviour of 4-1BB-CARs, Gomes-Silva et al demonstrated that very high 1 expression levels of 4-1BB-CARs also lead to apoptosis and limit CAR-T cells expansion⁴. The same authors also showed that lowering it expression levels by using EF1α-driven LVs instead of LTR-driven -retroviral vector, improved phenotype, expansion potential and therapeutic efficacy. These studies showed that EF1α-driven LVs already generate a good CAR product for some 4-1BB-CARs. Here we show that TCR-like expression can further improve 4-1BB-CAR-T products, in particular for the ARI-0001, by maintaining a better phenotype and controlling tonic signalling and pro-inflammatory cytokine secretion. An important aspect to consider in CAR-T cells is the potential side effects due to overstimulation and/or inadequate stimulation. Severe CRS (grades 3 or 4) is an important hallmark in CD19+ that can compromise efficacy and lead to life-threatening conditions^{28,29}. Upon tumour cell encounter, CAR-T cells release different pro-inflammatory cytokines such as TNFα, IFN , IL-1 and GM-CSF that leads to macrophage recruitment and activation causing a dangerous cytokine storm involving IL-6 and GM-CSF^{30, 31}. It has also been demonstrated that activation of macrophages through CD40/CD40L, CD69 and LAG-3 also contributes to massive activation²⁹. Although CRS can be managed with corticosteroids and anti-IL6R (Tocilizumab), 16 these interventions also block T cell activation compromising CAR-T efficacy ²⁹. In this manuscript, we have shown that CAR-T cells generated with AW-LVs exhibit a milder secretion of TNFα and IFN after tumour cells encounter. In addition, we noted that LAG-3 20 expression was reduced after Namalwa interaction which suggests that AW-CAR-T cells could 21 lower the risk of CRS. 22 We finally investigated the feasibility of generating a viable CAR-T cell product for clinical 23 translation. Here, we have demonstrated that it is feasible to generate TCR-like CAR-T cells in 24 a CliniMACs Prodigy, with high cell viability, predominant stem and CM populations and 25 potent in vitro and in vivo anti-tumour activity. In contrast and consistent with our comparative results, ARI-0001 generated more memory and effector memory population¹⁹, highlighting another potential advantage of AW-CAR-T cells during the manufacturing process. On the other

4

5

6

7

8

9

11

12

13

14

15

16

17

18

21

24

1 hand, the efficacy of transduction was lower compared to ARI (~ 18.4% vs ~30.6%), suggesting 2 that a future optimization of the AWARI LV backbone could further improve the manufacturing process of AW-CAR-T cells. Taken all together, we propose the use of AW-LVs as an alternative platform for the manufacturing of CAR-T cells in order to provide better efficacies and/or safety of the final products. The final benefits of expressing different CARs through the AW promoter will need to be determined in each case. **Conclusions** 10 In this work we showed that LVs expressing the transgene through the WAS gene proximal promoter mimic very closely the TCR expression pattern kinetic in T cells. 4-1BB-CAR-T cells generated with WAS-promoter-driven LVs (AWARI CAR-T) exhibited a higher proportion of Naïve/Stem Cell Memory T cells, less exhausted phenotype, lower tonic signalling and reduced secretion of pro-inflammatory cytokines compared to EF1-driven ARI CAR-T. Finally, AWARI CAR-T cells were efficiently manufactured in large-scale GMP-like conditions. Altogether, our data showed that the AW-LVs can be used to generate improved, physiological 4-1BB-CAR-T cell products and propose these LVs as efficient tools for the generation of clinical-grade TCRlike CAR-T cells. 19 20 **DECLARATIONS** Ethics approval and consent to participate 22 All donors from the Haematology Unit of Hospital Reina Sofía, Córdoba (Spain) gave their 23 written informed consent and the study was performed according to the established guidelines of in the approved by the Regional Government Junta de Andalucía-Consejeria de Salud (date of approval: 22/02/2019, signed by Da Cristina Lucía Dávila Fajardo as secretary of the

1

2 Research Ethics Committee), that comply with the requirements regarding quality and safety for 3 donation, obtaining, storage, distribution, and preservation of human cells and tissues under the 4 Spanish specific regulation (RD 9/2014) and International Conference of Good Clinical 5 Practice. All the experiments involving animals were performed according to a protocol 6 approved by the Institutional Animal Care and Use Committee of the University of Granada 7 (13/12/2016/181) were in accordance with the European Convention for the Protection of 8 Vertebrate Animals used for Experimental and Other Scientific Purposes (CETS # 123) and the 9 specific Spanish law (R.D. 53/2013). Subjects were randomly assigned to receive the different treatments and sample size estimation was calculated based on Mayer et al²⁰. 10 11 **Consent for publication** 12 All the authors consent the publication of this manuscript. Availability of data and material 13 14 All data relevant to the study are included in the article or uploaded as online supplemental 15 information. Figures were created with Biorender.com. 16 **Competing interests** 17 FMM, MTM, NMP, PM and KB are inventors of a patent for AW promoter for CAR-T cells 18 applications. P.J.L is contractually associated to LentiStem Biotech, a Spin-Off company that 19 has the license of that patent. The rest of the authors declare that the research was conducted in 20 the absence of other commercial or financial relationships that could be construed as a potential 21 conflict of interest. 22 **Funding** 23 This study was funded by the Spanish ISCIII Health Research Fund and the European Regional 24 Development Fund (FEDER) through research grants PI12/01097, PI15/02015, PI18/00337 1 (F.M.), PI18/00330 (K.B.) and PI17/00672 (P.M.); The CECEyU and CSyF of the Junta de

2 Andalucía FEDER/European Cohesion Fund (FSE) for Andalusia provided the following

research grants: 2016000073391-TRA, 2016000073332-TRA, PI-57069, PAIDI-Bio326,

4 CARTPI-0001-201 (F.M.), PI-0014-2016 (K.B) and PEER-0286-2019 (P.M.), PE-0223-2018;

5 The Ministerio de Ciencia, Innovación y Universidades (CDTI) to F.M. (00123009 / SNEO-

6 20191072). K.B. and C.M held Nicolas Monardes contracts from regional Ministry of Health

(#0006/2018 and C2-0002-2019 respectively). M.T.M., N.M.P and A.A.G. are funded by

Spanish Ministry of Education and Science through fellowships FPU16/05467, FPU17/02268

9 and FPU17/04327 respectively. P.J.L is funded through an industrial doctorate MCI DIN2018-

010180 to LentiStem Biotech. P.M is funded by Fundación Andaluza Progreso y Salud. M.C.G

is funded by Spanish Ministry of Education and Science through fellowship GJ (PEJ-2018-

12 001760-A). MDC is funded by the grant PE-0223-2018 CSyF of the Junta de Andalucia.

13 M.T.M., N.P.M., P.L.J.L., M.C.G. and A.G.G. are PhD students from the Biomedicine

14 Programme of the University of Granada (Spain).

Authors' contributions

3

7

8

10

15

18

19

20

21

22

23

24

26

16 MTM and NMP designed and performed experiments, analysed data and wrote the manuscript.

17 PLJL performed and analysed experiments and critical review of the manuscript. PM

contributed to animal experiments. MCG and KP contributed to T cells isolation and revised the

manuscript. RJM and SN designed and produced CliniMACs Prodigy large scale CAR-T cells

production process. RJM, SN and MDC performed the phenotypic characterization of

CliniMACs-derived products. SSH and AAG contributed to AWARI LVs production. MC and

MJ provided ARI-0001 LV and critical review. CM provided material and critical review. KB

provided funding and critical review. CH provided funding and critical review of the

manuscript. FM conceals the project, designed experiments, analysed data, provides the main

25 funding and wrote the manuscript.

Acknowledgements

- 1 We thank Ana Fernández-Ibáñez for her support with the IVIS Spectrum Analyzer, Nieves
- 2 Álvarez for her help of ELISA assays. We also thank GENYO's supporting units.

References

3

4

5

6 7

8 9

12

13

14

25

26

27

28

29 30

34

35

36

37 38

- 1. Vitale C, Strati P. CAR T-Cell Therapy for B-Cell non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Clinical Trials and Real-World Experiences. Front Oncol 2020;10:849.
- 2. Eyquem J, Mansilla-Soto J, Giavridis T, et al. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature 2017;**543**(7643):113-17.
 - 3. Frigault MJ, Lee J, Basil MC, et al. Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells. Cancer Immunol Res 2015;**3**(4):356-67.
- 4. Gomes-Silva D, Mukherjee M, Srinivasan M, et al. Tonic 4-1BB Costimulation in Chimeric
 Antigen Receptors Impedes T Cell Survival and Is Vector-Dependent. Cell Rep
 2017;21(1):17-26.
- 5. Ajina A, Maher J. Strategies to Address Chimeric Antigen Receptor Tonic Signaling. Mol Cancer Ther 2018;**17**(9):1795-815.
- 6. Benabdellah K, Gutierrez-Guerrero A, Cobo M, et al. A chimeric HS4-SAR insulator (IS2) that prevents silencing and enhances expression of lentiviral vectors in pluripotent stem cells. PLoS ONE 2014:9(1):e84268.
- 7. Naldini L, Trono D, Verma IM. Lentiviral vectors, two decades later. Science 24 2016;353(6304):1101-2.
 - 8. Frecha C, Toscano MG, Costa C, et al. Improved lentiviral vectors for Wiskott-Aldrich syndrome gene therapy mimic endogenous expression profiles throughout haematopoiesis. Gene Ther 2008;15(12):930-41.
 - 9. Romero Z, Torres S, Cobo M, et al. A tissue-specific, activation-inducible, lentiviral vector regulated by human CD40L proximal promoter sequences. Gene Ther 2011;**18**(4):364-71.
- 31 10. Benabdellah K, Cobo M, Munoz P, et al. Development of an all-in-one lentiviral vector 32 system based on the original TetR for the easy generation of Tet-ON cell lines. PLoS 33 ONE 2011;6(8):e23734.
 - 11. Munoz P, Tristan-Manzano M, Sanchez-Gilabert A, et al. WAS Promoter-Driven Lentiviral Vectors Mimic Closely the Lopsided WASP Expression during Megakaryocytic Differentiation. Mol Ther Methods Clin Dev 2020;19:220-35.
 - 12. Benabdellah K, Munoz P, Cobo M, et al. Lent-On-Plus Lentiviral vectors for conditional expression in human stem cells. Sci Rep 2016;**6**:37289.
- 39 13. Tristan-Manzano M, Justicia-Lirio P, Maldonado-Perez N, et al. Externally-Controlled Systems for Immunotherapy: From Bench to Bedside. Front Immunol 2020;**11**:2044.
- 41 14. Calvez R, Lafouresse F, De Meester J, et al. The Wiskott-Aldrich syndrome protein permits 42 assembly of a focused immunological synapse enabling sustained T-cell receptor 43 signaling. Haematologica 2011;**96**(10):1415-23.
- 44 15. Cotta-de-Almeida V, Dupre L, Guipouy D, et al. Signal Integration during T Lymphocyte
 45 Activation and Function: Lessons from the Wiskott-Aldrich Syndrome. Front Immunol
 46 2015;6:47.

1 16. Martin F, Toscano MG, Blundell M, et al. Lentiviral vectors transcriptionally targeted to hematopoietic cells by WASP gene proximal promoter sequences. Gene Ther 2005;12(8):715-23.

4

5

6 7

8

9

10

11


30 31

- 17. Navarro-Marchal SG-L, Carmen; Entrena, Jose-Manuel; Ruiz-Alcala, Gloria; Tristán-Manzano, Maria; Martín, Francisco; Pérez-Victoria, Ignacio; Peula-Garcia, José Manuel; Marchal, Juan A. Anti-CD44-conjugated olive oil liquid nanocapsules for targeting pancreatic cancer stem cells. Biomacromolecules 2021.
- 18. Demaison C, Parsley K, Brouns G, et al. High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency [correction of imunodeficiency] virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter. Hum Gene Ther 2002;13(7):803-13.
- 19. Castella M, Caballero-Banos M, Ortiz-Maldonado V, et al. Point-Of-Care CAR T-Cell
 Production (ARI-0001) Using a Closed Semi-automatic Bioreactor: Experience From
 an Academic Phase I Clinical Trial. Front Immunol 2020;11:482.
- 20. Mayer B, Stahl V, Kron M. The use of gatekeeping procedures in the statistical planning of animal experiments. Altern Lab Anim 2017;**45**(6):317-28.
- 21. Castella M, Boronat A, Martin-Ibanez R, et al. Development of a Novel Anti-CD19
 Chimeric Antigen Receptor: A Paradigm for an Affordable CAR T Cell Production at
 Academic Institutions. Mol Ther Methods Clin Dev 2019;12:134-44.
- 22. Marofi F, Motavalli R, Safonov VA, et al. CAR T cells in solid tumors: challenges and opportunities. Stem Cell Res Ther 2021;**12**(1):81.
- 23. Martinez M, Moon EK. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment. Front Immunol 2019;10:128.
- 24. Rodriguez-Garcia A, Palazon A, Noguera-Ortega E, et al. CAR-T Cells Hit the Tumor
 Microenvironment: Strategies to Overcome Tumor Escape. Front Immunol
 2020;11:1109.
- 28 25. Wagner DL, Fritsche E, Pulsipher MA, et al. Immunogenicity of CAR T cells in cancer therapy. Nat Rev Clin Oncol 2021.
 - 26. Finney OC, Brakke HM, Rawlings-Rhea S, et al. CD19 CAR T cell product and disease attributes predict leukemia remission durability. J Clin Invest 2019;**129**(5):2123-32.
- 27. Long AH, Haso WM, Shern JF, et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med 2015;**21**(6):581-90.
- 28. Lee DW, Santomasso BD, Locke FL, et al. ASTCT Consensus Grading for Cytokine
 Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.
 Biol Blood Marrow Transplant 2019;25(4):625-38.
- 29. Wei J, Liu Y, Wang C, et al. The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma. Signal Transduct Target Ther 2020;**5**(1):134.
- 40 30. Sterner RM, Sakemura R, Cox MJ, et al. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood 2019;**133**(7):697-709.
- 43 31. Hao Z, Li R, Meng L, et al. Macrophage, the potential key mediator in CAR-T related CRS.


 Exp Hematol Oncol 2020;**9**:15.

Physiological (TCR-like) regulated lentiviral vectors for the generation of improved CAR-T cells

LVs-Strong Promoter



LVs-TCR-like Promoter



Authors


María Tristán-Manzano, Noelia Maldonado-Pérez, Pedro Justicia-Lirio, Pilar Muñoz, Marina Cortijo, Kristina Pavlovic, Rosario Jiménez-Moreno, Sonia Nogueras, MDolores Carmona, Sabina Sánchez-Hernández, Araceli Aguilar-González, María Castella, Manel Juan, Concepción Marañón, Karim Benabdellah, Inmaculada Herrera and Francisco Martin.


Correspondence


f.martin@genyo.es


In Brief


Current CAR-T cells products use strong promoters to drive CAR expression which lead to high activation, tonic signalling and premature differentiation. Here, we propose the WAS promoter, which drives a partial decrease in CAR expression, as an alternative for the generation of TCR-like CAR-T cells in a LV context with improved characteristics.











FIGURES CAPTION

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

Figure 1. T cells transduced with WAS promoter-driven LVs mimic the TCR expression pattern. A) Top: Timeline of the experiments to study eGFP expression pattern after TCR/CAR stimulation. Bottom: diagrams of the different used eGFP-expressing LVs analyzed. B) Fold change of CD3 expression (% relative to 0h) in WT T cells stimulated with αCD3/αCD28 and αCD19CAR-T cells stimulated with CD19+ cells. Left: fold change in CD3 expression at different times poststimulation. (Data are MeFI± SEM *, indicates p<0,05, 2-way-ANOVA, Bonferroni post-Test. n≥5). Right: Representative histograms showing CD3 expression on WT T cells (left) and αCD19CAR-T cells (right) at different times post-stimulation. C) Representative histograms of eGFP expression driven by strong-promoter driven (CEWP, SE and EFEWP- top panels) and WAS-promoter driven (WE, AWE – bottom panels) LVs at different times post-stimulation. D, E) Graphs showing fold change in eGFP (colored lines) and CD3 (black lines) expression along time after αCD3/αCD28 stimulation of T cells transduced with viral promoter-driven (CEWP, SEWP) (D) or eukaryoticpromoters driven (EFEWP, WE and AWE) LVs (E). Fold change is calculated by the following formula: ((MeFI of GFP+ population xh/ MeFI of non-transduced cells xh)/ MeFI of GFP+ population 0h/ MeFI of non-transduced cells 0h). 2-way-ANOVA, Bonferroni post-Test, compared with CD3 pattern: *, p<0.05; **, p<0.01; ***, p<0.001. +++ indicates p<0.001 for SEWP compared to CD3 expression. n=5. F) Diagrams of the EF1a promoter-driven (ARI) and WAS-promoter driven (AWARI) LVs expressing the ARI-0001 CAR (αCD19 A3B1-41BB-CD3ζ) G) Representative histograms of CAR expression levels on CAR-T cells generated with the ARI (top) or AWARI (bottom) LVs and measured at different time points after activation with CD19+ cells (left) or αCD3/αCD28 (right). H, I) Graphs showing fold change in CAR expression on ARI-CAR-T (green lines) and AWARI-CAR-T (blue lines) cells at different time points after activation with CD19+ cells (H) or αCD3/αCD28 (I). Data shows the percentage of CAR+ cells at different time points relative to 0 hours. Man-Whitney test, two tails, ** indicates p<0.01 compared to CD3 and + indicates p<0,05 compared to AWARI-CAR-T cells. $n\geq 5$.

5

6

7

8

9

15

17

Figure 2. TCR-like expression improves CAR-T cells properties in vitro. A) Top: 1 2 Representative histograms of LAG-3, PD1 and Tim3 expression of NTD (non-transduced, 3 gray), ARI (blue) and AWARI (green) CAR-T cells determined 10 days after activation with αCD3/CD28. Bottom: Graphs showing expression levels of LAG-3, PD1 and Tim3 of ARI and AWARI CAR-T cells related to the expression in NTD cells. Data are MeFI ± SEM. One-tailed Man-Whitney test (4 independent-donors). B) Left: Representative histograms of intracellular phospho-CD3z expression after 10 days post-initial activation of NTD (gray), ARI (blue) and AWARI (green) CAR-T cells. Right: Graph showing pCD3z expression levels of each CAR-T cells related to NTD cells. Represented data is the ratio of pCD3z 10 MeFI of ARI or AWARI CAR-T cells divided by the pCD3z MeFI of NTD cells. One-tailed 11 Man-Whitney test (4 independent-donors, n≥4). C) Lysis of CD19+ cells (Nalm6 and 12 Namalwa) at different ratios of co-culture with ARI and AWARI-CAR-T cells during 48h. 13 Percentage of lysis is related to NTD-driven non-specific CD19+ lysis (n=5). D) Relative expression levels of LAG-3 on ARI and AWARI CAR-T cells 48h after co-culture with 14 Nalm6 (left) or Namalwa (right) cells. Data represents LAG-3MeFI of ARI or AWARI 16 CAR-T cells divided by the LAG-3 MeFI of NTD cells. One-tailed Man-Whitney test (n≥5). E) Levels of secreted TNFα (left) and IFN□ (right) produced by NTD, ARI and AWARI 18 CAR-T cells after 24h of stimulation with Namalwa at ratio 1:1 and determined by ELISA (4 19 independent-donors, $n \ge 4$). 20 21 Figure 3. In vivo anti-tumor activity and phenotype of ARI and AWARI CAR-T cells. 22 A) Experimental design of in vivo antitumor activity and phenotypic studies of 5e6 (purple 23 dots) and a 10e6 (blue dots) of ARI and AWARI CAR-T cells. Re-challenge with new 24 Namalwa is indicated with an arrow at day 16 in the 10e6 dose. Phenotypic analysis was 25 performed after sacrifice at day 13 for 5e6 dose and day 28 for 10e6 dose. B) Tumor 26 bioluminescence (BLI) progression with 5e6 (left) and 10e6 T cells doses (right) at different 27 days post-Namalwa inoculation. C) Percentage of surviving Namalwa-GFP-Nluc cells in

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

bone marrow (BM), spleen, blood, liver and blood determined by FACS after the sacrifice with the low (left panels) and high (right panels) doses. This value is analyzed in "singlets human cells" gate (see M&M). Two-tailed Mann-Whitney test, *, p<0.05; **, p<0.01, and ***, p<0.001. N(mice) of low dose: PBS=3, NTD=3, ARI=3, AWARI=3; and high dose: PBS=2, NTD=3, ARI=8, AWARI=5. D) Representative dot-plots of CAR expression and phenotype of CAR+ cells of gated hCD3 from the spleen of ARI and AWARI mice after sacrifice of the high-dose experiment. E) Graphical representation of proportions of T_N/T_{SCM} (CD62L+CD45RA+) (green), T_{CM} (CD62L+CD45RA-) (blue), T_{EM} (CD62L-CD45RA-) (grey) and T_{EF} (CD62L-CD45RA+) (red) subpopulations in ARI (top) and AWARI (bottom) CAR+ cells in the indicated organs after sacrifice of challenged (outer circle) and rechallenged (inner circle) mice. *, p<0.05 when compared the T cells subsets of re-challenged ARI and AWARI treated mice. Mann-Whitney one-tail. ++ and +++ p<0.01 and p<0.001 respectively of 2-way ANOVA, Bonferroni post-Test of all the population of the total mice (ARI=8 (3+5R), AWARI=5 (2+3R). F) Percentage of T_N/T_{SCM} and T_{CM}after sacrifice of ARI and AWARI hCD3+CAR+ cells (ARI=8, AWARI=5, Mann-Whitney one-tail. G) Spleen from treated mice were isolated and cells suspensions were cultured with 200 UI/ml of IL-2 in TexMACS medium and 2% P/S during 48h. H) Representative dot-plots of CD45RA/CD62L and PD1/LAG3 populations of ARI and AWARI mice. I) Percentage of hCD3+ T_N/T_{SCM} and T_{CM}after 48h of *in-vitro* culture. Two-tailed Mann-Whitney test (N=4). J) Percentage of PD1+LAG3+ cells. One-tailed Mann-Whitney test (N=4). Figure 4. GMP-like large-scale production of AWARI CAR T cells. A) Time-line of the GMP-like batches #01 and #02 of AWARI CAR-T cells in the CliniMACS Prodigy. B) Dotplots of CAR expression at days of sample (7/6) and final product (10/9) for both #01 (left) and #02 (right) batches. C) Data from viability, number of CD3, efficiency of CAR-T cell transduction and number of obtained CAR-T cells. FC= flow cytometry, NC= Neubauer chamber counting. D) Variation of percentage of CD4 and CD8+ cells in CAR- and CAR+ cells 1 at sample (s) and final products (f). Two-tailed Mann-Whitney test. E) Graphical representation

2 of the T cells populations at sample (days 6 or 7) and final products (day 9 or 10).

3 T_N/T_{SCM}=Naïve/stem cell memory (CD45RA+CCR7+), T_{CM}= central memory (CD45RA-

CCR7+), T_{FM}= effector memory (CD45RA-CCR7-) and T_{FMRA}= effector memory

5 RA+(CD45RA+CCR7-). F) In vitro specific lysis of CD19+ cells Nalm6 (left) and Namalwa

(right) CD19+ cells by AWARI CAR-T cells harvested at sample day (black line) and final day

7 (red line) for productions #01 and #02. CAR-T cells products were co-cultured at different

Figure 5. In vivo anti-tumor activity and phenotype of CliniMACS-produced AWARI-

ratios during 16h (dashed line) or 48h (continuous line).

4

6

8

9

10

11

12

13

14

17

26

27

***, p<0.0001.

CAR-T cells after one or two Namalwa challenges. A) Experimental design and time-line of the two experiments with CliniMACS batches #01 and #02. R indicates re-challenge. B) Survival of PBS, NTD or AWARI-inoculated mice of #01 and #02 products. Log-Ranked test. C, D) Representative BLI images of tumor burden measured in #01 (C) and #02 (D) 15 16 experiments at different days post Namalwa inoculation as indicated. In both studies, at day 15 (#01) or 13 (#02) respectively, new Namalwa cells were inoculated to AWARI treated mice (re-18 challenge, yellow line) and to control mice ('New PBS'). E) Representative dot-plots of 19 Namalwa/hCD3 presence, CAR+ cells of hCD3 and phenotype of CAR- and CAR+ of NTD 20 cells and AWARI CliniMACS #01 from BM after sacrifice. F) Percentage of T_N/_{SCM}+T_{CM} 21 population in hCD3+CAR+ cells analyzed in different organs from mice with one or two 22 (rechallenge, R) inoculations of Namalwa tumor cells in #01 (left) and #02 (right) CliniMACS 23 batches at final day. Only when CAR+ population was >1%, data was analyzed and included 24 here. N (CliniMACS #01): PBS=3, NTD=5, AWARI=10 (2 sacrificed at day 13, 4 mice with 25 one- and 4 mice with two-challenges. N (CliniMACS #02): PBS=2, NTD=3, AWARI =5 (2+3)

re-challenged mice). 2-way-ANOVA, Bonferroni Post Test, *, indicates p<0.05, **, p<0.001,